US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire Cortex, Inc., a medical technology company under the Ajax Health umbrella. The financial details of the agreement have not been disclosed, and the transaction is expected to close in the first half of 2025.
Cortex, Inc.’s Innovation in Atrial Fibrillation Diagnostics
Founded in December 2023 with investment from Ajax Health, Cortex is dedicated to developing diagnostic mapping solutions for atrial fibrillation (AF). The company’s OptiMap System employs a basket catheter and a proprietary algorithm to pinpoint potential active AF sources, offering physicians detailed insights to facilitate personalized ablation strategies for their patients. This technology is designed to identify triggers and drivers of AF outside of the pulmonary veins, which are crucial to the condition’s foundation.
Enhancing Boston Scientific’s Electrophysiology Portfolio
The integration of Cortex’s technology will enhance Boston Scientific’s electrophysiology portfolio by adding a differentiated cardiac mapping solution. This will aid in managing complex AF cases, providing a valuable addition to the company’s existing offerings in cardiac care.- Flcube.com
